跳至主要内容
临床试验/CTRI/2024/10/075360
CTRI/2024/10/075360尚未招募3 期

Evaluation of the Clinical Efficacy of Vachaharidradi Gana Kwatha Oral and Triphaladya Taila Matravasti in the Management of Medoroga w s r to Hyperlipidemia

Dr Rena Ravali1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年10月26日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
To reduce the symptoms of Hyperlipidemia

研究概览

简要总结

Medoroga is a condition in which there is an excessive production of medodhatu in the body. Accumulation of medodhatu in different parts of the body causes blockage of srotas which ultimately leads to poor nourishment of other dhatus. Kaphavardhaka ahara and vihara are the two main causes of Medoroga. Symptoms like KshudraSwasa, Trshna,  Moha, Atinidra, Krathana, Sadana, Kshud, Atisweda, Dourgandhya, Alpa Prana and Alpa Maithuna are seen in Medoroga. In modern times, the way of life has changed drastically to quick nourishments and inactive tendencies throughout the world. Because of these factors, accumulation of medodhatu happens immensely. Hyperlipoproteinemia or Hyperlipidemia involves abnormally elevated levels of any or all lipids and / or lipoproteins in the blood. It is the most common form of Dyslipidemia. Hyperlipidemia is divided into Primary and Secondary subtypes. Primary Hyperlipidemia is usually due to genetic causes ( such as a mutation in receptor protein), while secondary Hyperlipidemia arises due to other underlying causes such as Diabetes, Thyroid, Renal disorders, Liver disorders and  Cushing’s syndrome. Hyperlipidemia is one such condition that has been described as a possible risk factor for a wide range of diseases including Cardio vascular diseases,  Cerebrovascular accident, Metabolic syndrome and Hypertension. Hyperlipidemia is described as elevated serum levels of Cholesterol or Triglycerides or both.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Patients having Prathyatma Lakshanas of Medoroga (Kshudra swasa, Trishna, Krathanam, Atinidra, Swedadikya).
  • 2.Ptients having alteration in one or more component of the lipid profile.
  • Triglycerides 150-450mg/dl, Total Cholesterol 200-399 mg/dl, low density lipoprotein 100-190mg/dl
  • Patients indicted for Vasti karma
  • Patients who are willing to participate in the study and agree for consent sign.

排除标准

  • 1.Patients with uncontrolled Non insulin dependent Diabetes Mellitus, Hypertension and Hypothyroidism.
  • 2.Patients having Congenital hyperlipidemia ( like xanthomas ) ,Systemic disorders, Chronic kidney diseases, Drug induced hyperlipidemia eg; glucocorticoids etc.
  • and who is suffering from HIV, Carcinoma.
  • 3.Known gene mutations are excluded.
  • 4.Pregnant women and lactating mothers.
  • 5.Patients contraindicated for vasti karma.

结局指标

主要结局

To reduce the symptoms of Hyperlipidemia

时间窗: 90 days

次要结局

  • To Reduce raised Total cholesterols, triglycerides, LDL Counts(90 days)

研究者

发起方
Dr Rena Ravali
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Rena Ravali

Dr BRKR Govt Ayurvedic Medical College & Hospital

研究点 (1)

Loading locations...

相似试验